Ligelizumab treatment for severe asthma: learnings from the clinical development programme

Ligelizumab treatment for severe asthma: learnings from the clinical development programme

Abstract Objective Ligelizumab is a humanised IgG1 anti‐IgE antibody that binds IgE with higher affinity than omalizumab. Ligelizumab had greater efficacy than omalizumab on inhaled and skin allergen provocation responses in mild allergic asthma. This multi‐centre, randomised, double‐blind study was...

Full description

Bibliographic Details
Main Authors: Jordis Trischler, Ivan Bottoli, Reinhold Janocha, Christoph Heusser, Xavier Jaumont, Phil Lowe, Aurelie Gautier, Abhijit Pethe, Ralph Woessner, Hans‐Günter Zerwes, Stefan Zielen
Format: Article
Language:English
Published: Wiley 2021-01-01
Series:Clinical & Translational Immunology
Subjects:
asthma
biologics
CD23
ligelizumab
omalizumab
Online Access:https://doi.org/10.1002/cti2.1255

Internet

https://doi.org/10.1002/cti2.1255

Similar Items